I would think one of these days soon we could see Saguaro Capital(Mr Caven's Co., and who is the CFO at Regen) step up to the plate with RGBP/ENTB given their business is to raise capital for medical device and pharmacology start-ups.
Bio
Todd S. Caven is an accomplished executive with 30 years of experience in corporate finance, taxation, mergers & acquisitions, corporate valuations and financing activities for various types of transactions. [b]In March of 2009, Mr. Caven co-founded Saguaro Capital Partners, an Arizona based firm that raises growth capital for medical device, pharmacology and technology based companies throughout the western United States.
Critical mass is now being formed at RGBP with a cadence of news on developments. Question is will they go it alone, partner, or be bought out. The markets for HemaXellerate and NRF26 are now looking to have $$$ HUGE $$$$ market potential.
The gene silencing NRF26 biotech can be applied to the canines and felines too so hopefully that is to be leveraged. Regen has a drug innovation agreement with Eli Lilly and Lilly also has an animal div.(Elanco). Lilly may just scoop all of this up. Time will tell.
2+2 ??
GLA
